Advertisement Caraco Markets Rivastigmine Tartrate Capsules - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Caraco Markets Rivastigmine Tartrate Capsules

Caraco Pharmaceutical, a Detroit-based company that develops, manufactures, markets and distributes generic pharmaceuticals, has started shipping Rivastigmine tartrate capsules.

Rivastigmine tartrate is suggested for treatment of mild to moderate Alzheimer’s dementia and mild to moderate Parkinson’s disease dementia.

Caraco Pharma Rivastigmine tartrate capsules are available in 1.5mg, 3mg, 4.5mg and 6mg strengths.

Rivastigmine is said to have demonstrated treatment effects on the cognitive (thinking and memory), functional (activities of daily living) and behavioural problems that are commonly associated with Alzheimer’s and Parkinson’s disease dementias.

Rivastigmine tartrate capsules, approved by FDA for Sun Pharma’s abbreviated new drug application (ANDA), are therapeutically equivalent to Novartis Exelon capsules.